Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 08:29:17 UTC - HELPFUL

Rated by Participant: 622C238DD86AE24DB752F006CCDCE1E75C610C8605C713D8B9DD359C002957DA
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 622C238DD86AE24DB752F006CCDCE1E75C610C8605C713D8B9DD359C002957DA
createdAtMillis - 1688891357340
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 1
helpfulUniqueContext - 0
helpfulAddressesClaim - 1
helpfulImportantContext - 1
helpfulUnbiasedLanguage - 1
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 1677803233077522432622C238DD86AE24DB752F006CCDCE1E75C610C8605C713D8B9DD359C002957DA